CSF EULAR 2023 RA Highlights
- No tags were found...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>EULAR</strong> <strong>2023</strong><br />
Congress Preview<br />
Rheumatoid Arthritis<br />
Faculty Introduction<br />
Dear Colleagues,<br />
Welcome to this year’s selection of <strong>EULAR</strong> abstracts on <strong>RA</strong> and my ‘<strong>Highlights</strong>’. We have selected a variety of abstracts<br />
that cover a range of key topics in the management of rheumatoid arthritis.<br />
The relationship between JAK inhibition and cardiovascular risk factors is a key topic on Wednesday, with two talks<br />
by Laura Muñoz-Barrera (OP0023) and Maya Buch (OP0043). Beyond this, Mattias Skielta also provides us an oral<br />
presentation asking the question ‘Does antirheumatic medical treatment of Rheumatoid arthritis affect survival after first<br />
acute myocardial infarction’ (OP0024).<br />
The interest in the cardiovascular does not stop there. Thursday features posters by Samar Aboulenain (POS0059) and<br />
George Karpouzas (POS0034), discussing cardiovascular risk in advanced therapy retention and the impact of biologics<br />
on inflammation and ischemic cardiovascular risk respectively. Sung Soo Ahn further develops our understanding with<br />
their presentation entitled ‘Cancers and cardiovascular diseases in patients with seropositive rheumatoid arthritis treated<br />
with JAK inhibitors and biologics.’<br />
Friday features more on the topic of JAK inhibition and the cardiovascular system, with presentations by Romain Aymon<br />
(OP0219) and Calin Popa (OP0221) offering further information on top of Wednesday’s insights. Several presentations<br />
highlight new data and insights on JAK inhibitors, with posters considering combination therapy (POS1015) as well as the<br />
long-term safety of tofacitinib (POS0232). The day also sees an oral presentation on the topic of JAK inhibition and herpes<br />
zoster vaccination presented by <strong>CSF</strong> Steering Committee member Kevin Winthrop (OP0225).<br />
Saturday finalises the congress with further data on JAK inhibition and beyond. This includes long-term filgotinib data<br />
(POS0308) and a poster describing the capacity of JAK2 Mutations, TNF-α, and IL-6 to predict patient responses to<br />
JAK inhibition (POS0358). Beyond JAK inhibition, there are posters presenting phase 2 data on Peresolimab (POS0307)<br />
as well as the latest from the RELATION study with Jacques-Eric Gottenberg (POS0315).<br />
Finally, this years <strong>EULAR</strong> features several important symposia. This includes the <strong>CSF</strong>’s The “Case” for JAK Inhibitors, where<br />
the faculty will discuss the optimisation of JAK inhibitor therapies. Indeed, this promises to be a fascinating discussion we<br />
don’t think you should miss. The end of this brochure features additional symposia we highly recommend you attend.<br />
As always, thank you for your continued support. We hope you have a fantastic time at <strong>EULAR</strong> <strong>2023</strong>!<br />
Kind regards<br />
Professor Xavier Mariette<br />
Université Paris-Saclay<br />
Ps. Make sure you get all the insights from this <strong>EULAR</strong> by downloading our other highlights brochures, and if you want to<br />
see the top picks for Lupus head on over to www.lupus-forum.com where you’ll find the top <strong>EULAR</strong> picks and their top<br />
abstracts in the field of lupus therapeutics.<br />
Register for FREE content at<br />
www.cytokinesignalling.com<br />
Follow us at:<br />
Cytokine Signalling Forum<br />
SPONSORSHIP AND UNRESTRICTED<br />
EDUCATIONAL G<strong>RA</strong>NTS FROM<br />
DEVELOPED UNDER<br />
THE AUSPICES OF THE
KEY:<br />
H<br />
<strong>Highlights</strong><br />
O<strong>RA</strong>L SESSION<br />
POSTER SESSION<br />
ABST<strong>RA</strong>CT SESSION<br />
Key Presentations<br />
Wednesday, 31 May <strong>2023</strong><br />
16:30–<br />
18:00<br />
OP0023<br />
16:30–<br />
18:00<br />
OP0043<br />
COMORBIDITIES IN RMD<br />
Chairs: Patrick Durez and Ioannis Parodis<br />
Unbiased hierarchical clustering of circulating molecular<br />
profiles in Rheumatoid Arthritis patients defines precise<br />
CV risk. Effects of TNFi, IL6Ri, and JAKinibs<br />
Laura Muñoz-Barrera<br />
FROM HEARTS TO LUNGS:<br />
COMORBIDITIES IN <strong>RA</strong><br />
Chairs: Christopher Edwards and Holland-Fischer<br />
Impact of cardiovascular comorbidities<br />
on efficacy of tofacitinib vs TNFi in<br />
rheumatoid arthritis<br />
Maya H Buch<br />
Thursday, 01 June <strong>2023</strong><br />
10:30–<br />
12:00<br />
OP0132<br />
OP0133<br />
12:00–<br />
13:30<br />
POS0051<br />
POS0059<br />
14:45–<br />
15:45<br />
POS0824<br />
POS0826<br />
THERE IS STILL A LOT TO SAY ABOUT<br />
BIOLOGICALS FOR <strong>RA</strong>!<br />
Chairs: Maya H Buch and Andreas Kerschbaumer<br />
Cancers and cardiovascular diseases in patients<br />
with seropositive rheumatoid arthritis treated with<br />
JAK inhibitors and biologics<br />
Sung Soo Ahn<br />
Do JAKis work the best among those <strong>RA</strong> patients<br />
where their safety concerns are the highest?<br />
Hannah Bower<br />
TAPERING, DRUG RETENTION AND<br />
PREDICTORS OF RESPONSE<br />
Chairs: Elise van Mulligen and Sytske Anne Bergstra<br />
Drug retention and reasons for discontinuation<br />
of biologics and JAK inhibitors in patients with<br />
rheumatoid arthritis – the ANSWER cohort study<br />
Kosuke Ebina<br />
Cardiovascular Risk and Advanced Therapies Retention<br />
in Rheumatoid Arthritis: Results From the OBRI<br />
Samar Aboulenain<br />
POSTER VIEW 4<br />
Cardiovascular (CV) And Malignancy Events<br />
in The Filgotinib (Fil) Rheumatoid Arthritis (Ra)<br />
Clinical Development Program Up To 8.3 Years<br />
Xavier Mariette<br />
Safety Profile of Upadacitinib Up To 6.5 Years of<br />
Exposure in Patients with Rheumatoid Arthritis<br />
Gerd Rüdiger Burmester<br />
H<br />
H<br />
POS0827<br />
POS0829<br />
POS0830<br />
POS0837<br />
POS0841<br />
Clinical Outcomes of Patients with Rheumatoid Arthritis<br />
Who Discontinued Tofacitinib or Tumour Necrosis<br />
Factor Inhibitors: Results from Oral Surveillance<br />
Andrea Rubbert-Roth<br />
Safety And Efficacy of Filgotinib: An Update from<br />
The Darwin 3 Phase 2 Long-Term Extension with<br />
A Maximum Of 8.2 Years of Exposure<br />
Rene Westhovens<br />
Baricitinib Versus Tnf-Inhibitors in Patients with Active<br />
Rheumatoid Arthritis and An Inadequate Response<br />
to Csdmards: 12 Weeks Results of a Pragmatic,<br />
Multicenter, Open Label, Noninferiority Trial<br />
Mart Van De Laar<br />
Impact Of JAKi, Tofacitinib, On CV Risk in Rheumatoid<br />
Arthritis: Jaki CV Risk Impact Study<br />
Ashit Syngle<br />
Effectiveness And Safety of Upadacitinib in Patients<br />
with Rheumatoid Arthritis and Prior Tnf-Therapy<br />
in Germany. Final Results from A Post-Marketing<br />
Observational Study<br />
Torsten Witte<br />
Friday, 02 June <strong>2023</strong><br />
09:30–<br />
10:30<br />
POS1015<br />
POS1041<br />
10:30–<br />
12:00<br />
OP0219<br />
OP0221<br />
POSTER VIEW 4<br />
A Novel Drug Combination of Iguratimod<br />
and Tofacitinib Alleviates Rheumatoid Arthritis<br />
and Secondary Osteoporosis<br />
Jie Chen<br />
Lipid metabolism is deeply altered in active<br />
Rheumatoid Arthritis patients and reversed by<br />
anti-TNF, anti-IL6R, and JAK-inhibitors<br />
Carlos Perez-Sanchez<br />
RHEUMATOID ARTHRITIS: NEW SMALL<br />
MOLECULES AND OLD DMARDS<br />
Chairs: Kim Lauper and Anja Strangfeld<br />
Incidence of major adverse cardiovascular H<br />
events in patients with rheumatoid arthritis<br />
treated with JAK-inhibitors compared to DMARDs:<br />
data from an international collaboration of<br />
registries (the “JAK-pot” study)<br />
Romain Aymon<br />
Therapy with JAK inhibitors and the risk of<br />
cardiovascular events in a Dutch rheumatoid<br />
arthritis population<br />
Calin Popa<br />
H
KEY:<br />
H<br />
<strong>Highlights</strong><br />
O<strong>RA</strong>L SESSION<br />
POSTER SESSION<br />
ABST<strong>RA</strong>CT SESSION<br />
OP0225<br />
10:30–<br />
12:00<br />
OP0203<br />
Evaluation of Response to Adjuvanted<br />
H<br />
Recombinant Zoster Vaccination in Patients<br />
With Rheumatoid Arthritis Receiving Upadacitinib:<br />
Results From a Randomized Trial Sub-study<br />
Kevin Winthrop<br />
UNDERSTANDING TREATMENT RESPONSE<br />
AND NOVEL TREATMENT APPROACHES IN <strong>RA</strong><br />
Chair: Reinhard Voll<br />
Immunophenotyping of rheumatoid arthritis stratifies<br />
five groups that have different responses to molecular<br />
targeted therapies<br />
Satoshi Kubo<br />
POS0311<br />
POS0312<br />
POS0315<br />
IL-6 inhibitors and JAK inhibitors: Which of these<br />
drugs, inhibiting a common pathway, has an<br />
advantage in preventing bone destruction in <strong>RA</strong>?<br />
Yoshinobu Koyama<br />
A real-life comparative study of JAK inhibitors and<br />
TNF inhibitors in rheumatoid arthritis with drug<br />
dispensing data from retail pharmacies in France<br />
Marie-Elise Truchetet<br />
Acute cardiovascular events risk in<br />
rheumatoid arthritis patients treated with<br />
tofacitinib or TNF inhibitors, a nationwide<br />
cohort study: RELATION study<br />
Jacques-Eric Gottenberg<br />
H<br />
12:00–<br />
13:30<br />
POS0232<br />
TREATMENT IN PSORIATIC ARTHRITIS<br />
ON THE MOVE<br />
Chair: Ann-Sophie De Craemer and Helena Achten<br />
Post-marketing safety surveillance of<br />
tofacitinib over 9 years in patients with<br />
rheumatoid arthritis and psoriatic arthritis<br />
Gerd Rüdiger Burmester<br />
H<br />
10:00–<br />
11:30<br />
POS0358<br />
GENETIC DETERMINANTS OF CLINICAL<br />
PHENOTYPES<br />
Chairs: Daniele Mauro and Tue Wenzel Kragstrup<br />
JAK2 Mutation, TNF-α and IL 6 Predict Response<br />
to JAK Inhibitor in Rheumatoid Arthritis Patients<br />
Yasmin Adel Abdelsalam Hussein<br />
12:00–<br />
13:30<br />
POS0176<br />
BDMARDS IN <strong>RA</strong> 2.0: ABOUT THE GOOD<br />
AND THE BAD<br />
Chairs: Alexandre Sepriano and Maya Buch<br />
Drug retention of biologics or JAKi in rheumatoid<br />
arthritis patients who failed treatment with JAKi:<br />
Results from the ANSWER cohort<br />
Naofumi Yoshida<br />
Saturday, 03 June <strong>2023</strong><br />
09:00–<br />
10:15<br />
LB0001<br />
10:00–<br />
11:30<br />
POS0307<br />
POS0308<br />
LATE-BREAKING O<strong>RA</strong>L ABST<strong>RA</strong>CTS<br />
Chairs: Caroline Ospelt and Christian Dejaco<br />
Head-to-Head Comparison of TLL-018 and Tofacitinib<br />
in Patients with Active Rheumatoid Arthritis: Interim<br />
Results from a Phase IIa Study<br />
Chris Liang<br />
ORIGINAL PERSPECTIVES ON OLD<br />
DMARDS AND NEW SMALL MOLECULES<br />
IN RHEUMATOID ARTHRITIS<br />
Chairs: L.M. Verhoef and L.M. Verhoef<br />
A Phase 2 Trial of Peresolimab for Adults<br />
with Rheumatoid Arthritis<br />
Paul Emery<br />
Long-term clinical profile of filgotinib (FIL) in<br />
patients (pts) with rheumatoid arthritis (<strong>RA</strong>)<br />
by cardiovascular (CV) risk factors: a post hoc<br />
subgroup analysis<br />
Maya H Buch<br />
H<br />
H<br />
Satellite Symposia<br />
WEDNESDAY, 31 MAY <strong>2023</strong><br />
18:30–<br />
19:45<br />
Why Benefit: Risk Assessment Should Drive<br />
Individualized Treatment Decisions<br />
Sponsor: AbbVie Chair: Kimme Hyrich<br />
THURSDAY, 01 JUNE <strong>2023</strong><br />
08:15–<br />
09:30<br />
17:30–<br />
18:45<br />
17:30–<br />
18:45<br />
Finding the Right Treatment for the Right Patient:<br />
What Similarities and Key Differences Among <strong>RA</strong>,<br />
PsA and AxSpA Determine Treatment Decisions<br />
Sponsor: Lilly Chair: Roberto Caporali<br />
Infliximab IV to SC: Mainstay Therapy in Rheumatology<br />
Sponsor: Celltrion Chair: Roberto Giacomelli<br />
Healthcare<br />
JAK to Reality: Seeking Clarity in <strong>RA</strong><br />
Sponsor: Galapagos Chair: Ennio Giulio Favalli<br />
FRIDAY, 02 JUNE <strong>2023</strong><br />
08:15–<br />
09:30<br />
08:15–<br />
09:30<br />
17:30–<br />
18:45<br />
The Great Debate: Force of Habit vs. Innovative<br />
Approach in the Management of Inflammatory<br />
Rheumatic Diseases<br />
Sponsor: Lilly Chair: Carlo Selmi<br />
Unpacking the Data: Who are the Appropriate Patients<br />
with <strong>RA</strong> for a JAK inhibitor?<br />
Sponsor: Pfizer Chair: Roberto Caporali<br />
The “Case” for JAK Inhibitors<br />
Sponsor: Lilly Chair: Elena Nikiphorou
KEY:<br />
H<br />
<strong>Highlights</strong><br />
O<strong>RA</strong>L SESSION<br />
POSTER SESSION<br />
ABST<strong>RA</strong>CT SESSION<br />
Abstract Sessions<br />
RHEUMATOID ARTHRITIS –<br />
PROGNOSIS, PREDICTORS AND OUTCOME<br />
AB0191<br />
AB0237<br />
Safety Outcomes in Patients (Pts) With Rheumatoid<br />
Arthritis (<strong>RA</strong>) Treated with Filgotinib (FIL) In Filosophy:<br />
Interim Results from A Prospective Observational Study<br />
P. Verschueren<br />
Effects of One-Year Tofacitinib Therapy on Angiogenic<br />
Biomarkers in Rheumatoid Arthritis<br />
G. Kerekes<br />
RHEUMATOID ARTHRITIS –<br />
COMORBIDITY AND CLINICAL ASPECTS<br />
AB0306<br />
Impact Of Tofacitinib on Lipid Metabolism in Patients<br />
with Rheumatoid Arthritis: A Real-World Study<br />
H. Huang<br />
RHEUMATOID ARTHRITIS – BIOLOGICAL DMARDS<br />
AB0421<br />
AB0425<br />
Real-World Effectiveness of Upadacitinib in<br />
Patients with Rheumatoid Arthritis<br />
D. C. Diederik<br />
Real-World Effectiveness of Filgotinib in Belgian<br />
Patients with Rheumatoid Arthritis<br />
D. C. Diederik<br />
RHEUMATOID ARTHRITIS –<br />
NON-BIOLOGIC TREATMENT AND SMALL MOLECULES<br />
AB0450<br />
AB0451<br />
AB0452<br />
AB0455<br />
AB0456<br />
Real-World Use of JAK Inhibitors in Rheumatological<br />
Practice in South London<br />
K. Biddle<br />
French Real Life Safety Data on The Use of Tofacitinib<br />
in Patients with Rheumatoid Arthritis: Observational<br />
Study, DEFACTO<br />
C. Gaujoux-Viala<br />
Survival Rate of Baricitinib in A Large Cohort of<br />
Rheumatoid Arthritis Patients: Analysis of Real-World Data<br />
S. Parisi<br />
Baricitinib In the Treatment of Patients with Moderate<br />
to Severe Active Rheumatoid Arthritis in China:<br />
24-Week Results of Post-Marketing Safety Study<br />
C. Y. Wu<br />
Baricitinib As Monotherapy for Treatment of<br />
Rheumatoid Arthritis: Summary of Data from<br />
Five Real-World Data Sources<br />
C. J. Edwards<br />
H<br />
H<br />
AB0460<br />
AB0470<br />
AB0472<br />
AB0474<br />
AB0476<br />
AB0477<br />
AB0479<br />
AB0483<br />
AB0487<br />
AB0493<br />
AB0496<br />
AB0501<br />
AB0504<br />
JAK Inhibitor Discontinuation Rates: Retrospective<br />
Real-World Data from A Tertiary Centre<br />
K. Bland<br />
Effect of Tofacitinib in Modulating Platelet Function in<br />
Patients with Rheumatoid Arthritis<br />
D. Mauro<br />
Filgotinib For Rheumatoid Arthritis – An Observational<br />
Study to Assess Clinical Effectiveness in NHS Lothian<br />
C. Box<br />
Real-World Single Center Use of Upadacitinib in<br />
Rheumatoid Arthritis Patients, Including Those<br />
Refractory to First-Generation JAK Inhibitors<br />
M. Kamiya<br />
After JAK Inhibitor Failure, ‘Switching’ Or ‘Cycling’?<br />
P. Muñoz Martinez<br />
Efficacy And Safety of Upadacitinib in Rheumathoid<br />
Arthritis: Real-Life Experience from A Multicentric<br />
Italian Study<br />
C. Baldi<br />
Baricitinib And Upadacitinib Affect the<br />
Levels of Bone Destruction Markers and<br />
Bone Formation Indicators in Patients with<br />
Rheumatoid Arthritis<br />
A. Felis-Giemza<br />
Filgotinib Is Effective and Safe in <strong>RA</strong> Patients<br />
After Failure to Multiple bDMARDs And to<br />
Other JAK Inhibitors: Data from A Monocentric<br />
Perspective Cohort Study<br />
F. Arru<br />
Evaluation Of Efficacy of Peficitinib for Rheumatoid<br />
Arthritis: A Multicenter, Retrospective Study in Japan<br />
M. Mitsuhashi<br />
The Efficacy and Safety of Tofacitinib in The Treatment<br />
of DMARDs Naive Rheumatoid Arthritis Patients<br />
(Eastern Study)<br />
J. Zhao<br />
Treatment With Upadacitinib in <strong>RA</strong> Patients<br />
for Which Biological Therapy Failed<br />
L. Robles Kirkegard<br />
Analysis Of Adverse Effects in Immune-Mediated<br />
Inflammatory Diseases Treated with JAK Inhibitors<br />
in A Single Center<br />
I. Pineiro<br />
Cardiovascular and Adverse Events Risk with Tofacitinib<br />
in Rheumatoid Arthritis in The Dominican Republic<br />
R. A. Alvarez Santana<br />
H<br />
H<br />
H<br />
Register for FREE content at www.cytokinesignalling.com<br />
DEVELOPED UNDER<br />
THE AUSPICES OF THE<br />
Follow us at:<br />
Cytokine Signalling Forum
Change language